A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies is a PHASE1 clinical asset sponsored by Shenzhen Geno-Immune Medical Institute in T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma. SEO and diligence focus: CD7-specific CAR gene-engineered T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.